| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/21/2006 | US20060211604 Methods for treating inflammatory disorders using regulators of microvessel dilations |
| 09/21/2006 | US20060211603 Ramoplanin derivatives possessing antibacterial activity |
| 09/21/2006 | US20060211602 Use of alanyl aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 09/21/2006 | US20060211601 Nitrosated and nitrosylated heme proteins |
| 09/21/2006 | US20060211600 Restoring function to injured cardiac tissue via exposure to mixture comprising secreted frizzled related protein (Sfrp) and a paracrine factor of a mesenchymal stem cells (MSC); tissue engineering and repair |
| 09/21/2006 | US20060211116 Transposase and method of gene modification |
| 09/21/2006 | US20060211114 Modulation of hedgehog-mediated signaling pathway |
| 09/21/2006 | US20060211091 MAGE-A3 peptides presented by HLA class II molecules |
| 09/21/2006 | US20060211090 Human cDNAs and proteins and uses thereof |
| 09/21/2006 | US20060211086 Process for manufacture of nematode-extracted anticoagulant protein (NAP) |
| 09/21/2006 | US20060211058 Diagnosis and treatment of malignant neoplasms |
| 09/21/2006 | US20060211051 Methods and reagents for preparing and using immunological agents specific for p-glycoprotein |
| 09/21/2006 | US20060211050 Methods of using 18903 to treat pain and pain-related disorders |
| 09/21/2006 | US20060211049 Estrogen related receptor, ERRalpha, a regulator of bone formation |
| 09/21/2006 | US20060211037 Novel mouse CXC chemokine receptor |
| 09/21/2006 | US20060211031 Novel proteins and nucleic acids encoding same |
| 09/21/2006 | US20060211020 Methods for the diagnosis, prognosis and treatment of metabolic syndrome |
| 09/21/2006 | US20060211015 detecting a difference between the levels of an expression product of a cancer associated (CA) gene in a cell in the presence and absence of an anticancer drug candidate; for carcinomas, especially lymphoma carcinomas |
| 09/21/2006 | US20060210975 Secreted and cytoplasmic tumor endothelial markers |
| 09/21/2006 | US20060210974 Compositions and methods for preventing, treating and diagnosing diabetes |
| 09/21/2006 | US20060210973 Inhibitors of proteins from the rho-gef family |
| 09/21/2006 | US20060210651 Methods and compositions involving aldose reductase |
| 09/21/2006 | US20060210650 Supplemental dietary composition for promoting weight loss |
| 09/21/2006 | US20060210647 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto |
| 09/21/2006 | US20060210643 Cartilage repair mixture containing allograft chondrocytes |
| 09/21/2006 | US20060210641 Absorbable microparticles |
| 09/21/2006 | US20060210629 Zinc-containing sustained-release composition, its preparation, and method for producing the same |
| 09/21/2006 | US20060210627 Direct compression formulation and process |
| 09/21/2006 | US20060210622 Surface modified particulate compositions of biologically active substances |
| 09/21/2006 | US20060210614 Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
| 09/21/2006 | US20060210603 Implantable medical articles having laminin coatings and methods of use |
| 09/21/2006 | US20060210601 Stretchable collagen material and manufacturing method and use thereof |
| 09/21/2006 | US20060210599 Injectable or sprayable nonpolymeric ester or mixed ester solution easily formulated with therapeutic agents |
| 09/21/2006 | US20060210589 With botulinum toxin |
| 09/21/2006 | US20060210587 Virus-like particles for the induction of autoantibodies |
| 09/21/2006 | US20060210575 Cytotoxic protein and utilization thereof |
| 09/21/2006 | US20060210573 Containing one or more epitopes recognized by and binding to a BAT monoclonal antibody; diagnosing and treating cancer; cancer vaccines; monoclonal, polyclonal, recombinant, synthetic intact antibody and Fv, F(ab'), F(ab')2 and single chain antibody fragments; polynucleotides |
| 09/21/2006 | US20060210568 Methods and compositions for cancer treatment |
| 09/21/2006 | US20060210565 Antagonists of HMG1 for treating inflammatory conditions |
| 09/21/2006 | US20060210564 Novel diabody-type bispecific antibody |
| 09/21/2006 | US20060210561 Dosages for treatment with anti-EGFR antibodies |
| 09/21/2006 | US20060210560 TNF receptor action modulaton |
| 09/21/2006 | US20060210552 Compositions and methods for systemic inhibition of cartilage degradation |
| 09/21/2006 | US20060210551 Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses |
| 09/21/2006 | US20060210550 Angiogenesis inducer |
| 09/21/2006 | US20060210549 Controlled release liposomes and methods of use |
| 09/21/2006 | US20060210548 Method for reducing obstructive hydrocephalus |
| 09/21/2006 | US20060210547 DNA encoding anti-apoptotic protein and recombinant 30K protein |
| 09/21/2006 | US20060210546 Athlete dietary supplement |
| 09/21/2006 | US20060210542 Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia |
| 09/21/2006 | US20060210539 Activating expression of an endogenous Pigment Epithelium Derived Factor gene in one or more cells of an organism; ocular neovascularization in an organism |
| 09/21/2006 | US20060210536 Methods and compositions for inhibiting stat signaling pathways |
| 09/21/2006 | US20060210535 Means for regulating the expression of human isoforms of ant |
| 09/21/2006 | US20060210534 Pegylated interleukin-10 |
| 09/21/2006 | US20060210533 Compounds and compositions for delivering active agents |
| 09/21/2006 | US20060210532 Means and methods for the recruitment and identification of stem cells |
| 09/21/2006 | US20060210531 Agent eleveting dendritic cell precursor level in blood |
| 09/21/2006 | US20060210526 polyoxyethylene glycol-protein conjugate linked via linking group |
| 09/21/2006 | US20060210510 Isolated polypeptide with glycosyl transferase enzymatic activity for producing dextrans with alpha (1 --> 2) sidechains, comprising at least one region for bonding to glucan and a catalytically active region situated beyond the region bonding to glucan; expression vectors; genetic engineering |
| 09/21/2006 | US20060210493 Peptide that binds to integrins |
| 09/21/2006 | US20060210475 Humanized L243 antibodies |
| 09/21/2006 | US20060210473 VEGF-conjugate combined methods for tumor vasculature targeting and tumor treatment |
| 09/21/2006 | CA2602312A1 Soluble btnl2 protein useful to inhibit inflammatory disorders |
| 09/21/2006 | CA2601784A1 Acylated glp-1 compounds |
| 09/21/2006 | CA2601525A1 Polypeptides having antimicrobial activity and polynucleotides encoding same |
| 09/21/2006 | CA2601227A1 Mecano growth factor peptides and their use |
| 09/21/2006 | CA2601069A1 Contrast agents for magnetic resonance imaging |
| 09/21/2006 | CA2600690A1 Recombinant e-selectin made in insect cells |
| 09/21/2006 | CA2598452A1 Treating anemia by inhibition of vegf |
| 09/21/2006 | CA2596926A1 Extended glp-1 compounds |
| 09/21/2006 | CA2563533A1 Compositions capable of facilitating penetration across a biological barrier |
| 09/20/2006 | EP1702985A2 Preferred segments of neural thread protein and methods of using the same |
| 09/20/2006 | EP1702983A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof |
| 09/20/2006 | EP1702929A2 Therapeutic use of the smr1 protein and active derivatives thereof |
| 09/20/2006 | EP1702928A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/20/2006 | EP1702914A1 Radio-opaque polymeric biomaterials |
| 09/20/2006 | EP1702625A1 Medicine containing genetically modified antibody against chemokine receptor ccr4 |
| 09/20/2006 | EP1702624A1 Immunotherapeutic stress protein-peptide complexes against cancer |
| 09/20/2006 | EP1702623A2 Use of interferon gamma for the treatment of cardiac hypertrophy |
| 09/20/2006 | EP1702622A1 Soluble BTNL2 protein useful to inhibit inflammatory disorders |
| 09/20/2006 | EP1702214A2 Methods of treating asthma |
| 09/20/2006 | EP1702067A1 Muteins of fibroblast growth factor 21 |
| 09/20/2006 | EP1702064A2 A biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan |
| 09/20/2006 | EP1701978A2 Use of t-cadherin as a target |
| 09/20/2006 | EP1701976A2 Peptide synthesis and deprotection with co-solvent |
| 09/20/2006 | EP1701974A2 Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments |
| 09/20/2006 | EP1701973A1 Glutathione derivatives and their uses for the treatment of viral diseases |
| 09/20/2006 | EP1701739A2 Use of agents derived from ceacam1 for the treatment of inflammatory diseases |
| 09/20/2006 | EP1701737A2 Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo |
| 09/20/2006 | EP1701736A1 Therapeutic agents and uses therefor |
| 09/20/2006 | EP1701735A2 Use of hydroxylated amino acids for treating diabetes |
| 09/20/2006 | EP1701734A1 Methods for treating vascular disorders |
| 09/20/2006 | EP1701733A1 Surface protection of exposed biological tissues |
| 09/20/2006 | EP1701732A2 Sulfhydryl protected glutathione prodrug |
| 09/20/2006 | EP1701731A1 Glp-1 (9-36) methods and compositions |
| 09/20/2006 | EP1701730A2 Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders |
| 09/20/2006 | EP1701714A2 Improved sustained release compositions for pulmonary administration of insulin |
| 09/20/2006 | EP1701691A1 Methods and compositions for oral hygiene |
| 09/20/2006 | EP1701688A2 Methods and compositions for directing migration of neural progenitor cells |
| 09/20/2006 | EP1450835B1 Compositions for the treatment of lupus |